Ipamorelin vs GHRP-6
Head-to-head comparison of Ipamorelin and GHRP-6 for research applications. Both peptides are studied for Body Composition, but they differ significantly in mechanism, evidence level, and dosing protocols.
Side-by-Side Comparison
| Attribute | Ipamorelin | Ghrp 6 |
|---|---|---|
| Category | Growth Hormone Secretagogue | Growth Hormone Secretagogue |
| Mechanism | Ipamorelin (sequence: Aib-His-D-2Nal-D-Phe-Lys-NH2) selectively binds to the Growth Hormone Secretagogue Receptor (GHS-R1a) on anterior pituitary somatotroph cells, increasing cAMP and activating protein kinase A to promote pulsatile GH secretion. | GHRP-6 functions as a synthetic ghrelin mimetic by binding to GHS-R1a in the pituitary and hypothalamus, triggering pulsatile GH release and raising IGF-1 levels. |
| Evidence Rating | D — Preclinical | D — Preclinical |
| Clinical Status | Research-only / Not approved for human use | Research-only / Not approved for human use |
| Safety Profile | Widely regarded as the mildest GHS available; minimal side effects in published animal and human studies; Common: injection site reactions (redness, swelling, bruising) in 15-30% of users, resolving within 24-48 hours | Intense hunger due to ghrelin receptor activation (more pronounced than other GH secretagogues); Transient mild increases in cortisol and ACTH (typically not clinically significant) |
| Route | Subcutaneous | Subcutaneous |
| Dose Range | 100–300 mcg per injection, 2–3x daily | 100–300 mcg per injection, 2–3x daily (saturation dose ~1 mcg/kg) |
| Frequency | 2–3 times daily (typically before meals and before bed) | 2–3 times daily |
| Molecular Weight | ~711.9 g/mol | ~873.0 g/mol |
| Half-Life | ~2 hours | ~15–60 minutes |
Overview
Ipamorelin and GHRP-6 are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
Ipamorelin — Mechanism & Evidence
Ipamorelin is the most selective growth hormone secretagogue (GHS) available, a synthetic pentapeptide (MW ~711.86 g/mol, formula C38H49N9O5) that stimulates pulsatile GH release from the pituitary gland without significantly affecting cortisol, prolactin, or appetite. It is widely regarded as the mildest GHS, making it popular in anti-aging, body composition, and recovery contexts. However, research on ipamorelin is limited, and it is not FDA-approved for any indication.
Key claims: Increases growth hormone levels; Improves body composition; Improves sleep quality.
BPC-157 5mg
5mg
GHRP-6 — Mechanism & Evidence
GHRP-6 (Growth Hormone-Releasing Peptide 6) is a synthetic hexapeptide that functions as a potent growth hormone secretagogue by binding to the ghrelin receptor (GHS-R1a). It stimulates pulsatile GH release from the pituitary while maintaining physiological feedback controls. It is one of the earliest GH-releasing peptides developed and is notable for strong appetite stimulation via ghrelin receptor activation. Beyond endocrine effects, GHRP-6 exhibits cytoprotective properties through the CD36 receptor, with preclinical data showing cardioprotective, neuroprotective, and anti-fibrotic effects.
Key claims: Increases growth hormone levels; Stimulates appetite; Cytoprotective and tissue-protective effects.
Shared Research Applications
Both peptides are studied for: Body Composition.
Ipamorelin is also researched for: Anti-Aging, Sleep.
GHRP-6 is also researched for: no additional unique applications.
Safety Considerations
Ipamorelin: Widely regarded as the mildest GHS available; minimal side effects in published animal and human studies Common: injection site reactions (redness, swelling, bruising) in 15-30% of users, resolving within 24-48 hours Common: mild temporary "head rush" or flushing immediately after injection due to sudden vasodilation
GHRP-6: Intense hunger due to ghrelin receptor activation (more pronounced than other GH secretagogues) Transient mild increases in cortisol and ACTH (typically not clinically significant) Water retention and bloating reported
Shop Research Peptides
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
Tesamorelin 10mg
10mg
BPC-157 10mg
10mg
Tirzepatide 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Tesamorelin vs Ipamorelin: Evidence, Uses, Risks
This article compares tesamorelin and ipamorelin based on published human evidence, highlighting what is known about their uses and risks and where direct comparative data is missing.
CJC-1295 and Ipamorelin: Human Evidence and Limits
This reference separates what human trials, animal models, and analytical chemistry show about CJC-1295 and ipamorelin from vendor marketing, assessing the strength of the human evidence base and combination-specific safety data.
CJC-1295 and Ipamorelin Dosage: Evidence and Risks
This reference reviews the evidence on CJC-1295 and ipamorelin dosing, distinguishing what controlled studies support from what remains speculative or vendor-derived.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe